NCT02478931 Study of Personalized Cancer Therapy to Determine Response and Toxicity
| NCT ID | NCT02478931 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shu Mei Kato |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2013-09-05 |
| Primary Completion | 2026-09-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2013-09-05 with a primary completion date of 2026-09-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to learn more about personalized cancer therapy including response to treatment and side effects. Information about the tests and treatments a person received, or will receive, for their cancer will be collected from medical records to help the researchers determine whether or not patients respond better when their physicians choose to treat them according to the genetic makeup of their tumor. Optional research tests may be performed on tissue, body cavity fluid, blood or urine provided, discarded biological samples taken during routine care that would normally be disposed of and not saved, or on blood samples collected for this study. These research tests will be used to create a "profile" of the collected specimens which will describe unique characteristics about the genes involved in a person's cancer. The tests will also help researchers look for biomarkers that may help predict how people respond to treatment.
Eligibility Criteria
Inclusion Criteria: * Must be willing to provide informed consent, parent permission, or assent Exclusion Criteria: * Subjects unable to give informed consent, parent permission, or assent
Contact & Investigator
Shumei Kato, MD
PRINCIPAL INVESTIGATOR
University of California, San Diego
Frequently Asked Questions
Who can join the NCT02478931 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02478931 currently recruiting?
Yes, NCT02478931 is actively recruiting participants. Contact the research team at sml012@health.ucsd.edu for enrollment information.
Where is the NCT02478931 trial being conducted?
This trial is being conducted at La Jolla, United States, Rancho Mirage, United States, San Diego, United States.
Who is sponsoring the NCT02478931 clinical trial?
NCT02478931 is sponsored by Shu Mei Kato. The principal investigator is Shumei Kato, MD at University of California, San Diego. The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.